News ImmuneRegen NewsImmuneRegen BioSciences Plans Response to Upcoming Department of Health and Human Services RFP for Advanced Development of New Antiviral Agents for InfluenzaSCOTTSDALE, Ariz., May 31 /PRNewswire-FirstCall/ -- Research and development bio-pharmaceutical company, ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTC Bulletin Board: IRBO), announced today that it is preparing to respond to the Department of Health and Human Services' (DHHS) request for proposal (RFP) titled Advanced Development of New Antiviral Agents for Influenza. According to the Presolicitation Notice, issued on May 15, 2006, the DHHS, through the Office of Public Health Emergency Preparedness and Office of Research and Development Coordination, will consider awarding single or multiple contracts to companies with compounds that show potential for the treatment and prevention of pandemic and seasonal influenza. Any DHHS contracts awarded will support the advanced research and development of the selected compounds as well as their production at one or more Food and Drug Administration (FDA)-licensed manufacturing facilities. Incremental multi-year funding for cost-reimbursement contracts will be provided to support this effort for an anticipated period of up to five years. The DHHS has stated they are particularly interested in the advanced development of new influenza antiviral agents designed to affect different targets of influenza virus infection. ImmuneRegen plans to submit their proposal by July 18, 2006 and will include the latest findings on its proprietary compound, Viprovex(TM) in regards to the potential treatment of influenza. ImmuneRegen's formal response will contain results from past studies, including completed pre-clinical testing on the Hong Kong influenza virus (A/Hong Kong/8/68, of the H3N2 type). About ImmuneRegen BioSciences, Inc.a wholly owned subsidiary of IR BioSciences Holdings, Inc., (OTC BB:IRBS.OB - News) is a development-stage biotechnology company focused on the research, development and licensing of Homspera™ and its derivatives. Homspera is an adult stem cell active compound that in study results has been shown to regenerate and strengthen the immune system and enhance wound healing. Viprovex®, a derivative of Homspera, is being developed for potential use against infectious diseases as a stand-alone or combination therapy and as a vaccine adjuvant. To advance its mission, the Scottsdale, Arizona based company has forged numerous study partnerships with industry and academic leaders, including Celgene Cellular Therapeutics, HemoGenix, Lovelace Respiratory Research Institute and Virion Systems. For more information, please visit www.immuneregen.com. Statements about ImmuneRegen's future expectations, including statements about the potential use and scientific results for ImmuneRegen's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. ImmuneRegen intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with ImmuneRegen's business, are subject to various risks and uncertainties. ImmuneRegen's actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials), the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in ImmuneRegen's periodic report on Form 10-Q for the three months ended June 30, 2008 and on Form 10-KSB for the year ended December 31, 2007 as filed with the Securities and Exchange Commission. There are no guarantees that any of ImmuneRegen's proposed products will prove to be commercially successful. ImmuneRegen undertakes no duty to update forward-looking statements. Contact: or
### Copyright © 2003-2008, ImmuneRegen Biosciences, Inc. All rights reserved. |
|